Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0428 USD | +4.99% | -.--% | -4.89% |
May. 17 | RepliCel Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Apr. 18 | RepliCel Life Sciences Inc. Announces Secured Loan Agreement | CI |
Sales 2022 | 354K 259K | Sales 2023 | 354K 259K | Capitalization | 3.87M 2.84M |
---|---|---|---|---|---|
Net income 2022 | - 0 | Net income 2023 | - 0 | EV / Sales 2022 | 9.26 x |
Net Debt 2022 | 300K 220K | Net Debt 2023 | 797K 584K | EV / Sales 2023 | 13.2 x |
P/E ratio 2022 |
-3.54
x | P/E ratio 2023 |
-11.3
x | Employees | 1 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 39.48% |
1 day | +4.99% | ||
3 months | +2.39% | ||
6 months | +9.18% | ||
Current year | -4.89% |
Managers | Title | Age | Since |
---|---|---|---|
Andrew Schutte
CEO | Chief Executive Officer | 35 | 18-12-13 |
Rolf Hoffmann
FOU | Founder | 63 | - |
Kevin McElwee
FOU | Founder | 54 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
David Hall
CHM | Chairman | 71 | 10-12-21 |
Peter Lewis
BRD | Director/Board Member | 69 | 11-05-26 |
Rolf Hoffmann
FOU | Founder | 63 | - |
1st Jan change | Capi. | |
---|---|---|
-4.89% | 2.78M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- REPCF Stock